AKT1 and lung cancer: Remarkably, miR-19b interacts with PP2A and BIM to simultaneously promote the phosphorylation of AKT, ERK and STAT [34], indicating its potential as a promising therapeutic target for affecting multiple pathways of EGFR TKI-resistant lung cancer.